MyoKardia, Inc (acquired by BMS)
1000 Sierra Point Parkway
Brisbane, CA 94005
About MyoKardia, Inc (acquired by BMS)
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. MyoKardia is a clinical-stage bio pharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the bio mechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224. Founded in September 2012 MyoKardia is headquartered in Brisbane, CA.
126 articles with MyoKardia, Inc (acquired by BMS)
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. “We are excited to welcome MyoKardia colleagues to Bristol Mye
EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation
MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with M arkers of HCM S everity in Non-Obstructive HCM Non-Clinical Data Show Mavacamten Surrogate Preserved Cardiac Function in Disease Model, Slowing Progression
MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy
MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovascular Registry operated by Veradigm®, an Allscripts (NASDAQ: MDRX), business unit. The registry will support MyoKardia’s post-marketing safety and effectiveness study (DISCOVER-HCM) of mavacamten, an investigational the
MyoKardia Reports Third Quarter 2020 Financial ResultsAcquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020
MyoKardia, Inc. reported financial results for the third quarter ended September 30, 2020.
Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 per share in cash, or approximately $13.1 billion. The ex
MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded to help advance MyoKardia’s mission to promote understanding and treatment of the underlying drivers of serious cardiovascular diseases. More than
MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation
MyoKardia, Inc. (Nasdaq: MYOK) today announced the upcoming presentation of clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in late-stage development for the potential treatment of hypertrophic cardiomyopathy, at the upcoming American Heart Association’s Scientific Sessions 2020. Two of the abstracts accepted for presentation focus on echocardiographic and cardiac magnetic resonance imaging (CMR)
Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Only a year after buying cancer specialist Celgene for $74 billion, Bristol Myers Squibb announced it is buying cardiology company MyoKardia for about $13.1 billion. The deal is expected to close before the end of the year.
MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.
MyoKardia, Inc. (Nasdaq: MYOK) today announced its participation in the following upcoming investor conferences: Citi’s 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020. Taylor Harris, Chief Financial Officer, will participate in a fireside chat at 4:15 p.m. EDT. Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020. Tassos Gianakakos, Chief Executive Officer, will participate in a fir
MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet
MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China
Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation: MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) and LianBio announced today that they have entered into a strategic collaboration to develop and commercialize mavacamten in China and other Asian te
Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020Virtual Analyst and Investor Event to Review Data Planned for 8:00 a.m. EDT on August 31
MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial during a late-breaker session at the upcoming European Society of Cardiology Congress 2020 (ESC Congress 2020).
MyoKardia, Inc. announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET.
MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020.
MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of MavacamtenVALOR-HCM Designed to Generate Direct Evidence of Improved Outcomes for People with HCM by Reducing the Need for Invasive Septal Reduction Therapy
MyoKardia, Inc. (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. VALOR-HCM will enroll individuals with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal reduction therapy (SRT) and are refractory to current therapeutic options, including those who have severe symptoms (NYHA Class IV). VALOR-HCM is designed to provide direct clinical evidence of mavacamten’
MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT). Conference Call and Webcast Analysts and investors are invited to participate in the conference call by calling 844-494-0193 from the U.S. and Canada
MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM